Supply Chain Ecosystem Analysis now part of DBMR Reports
Market Size in USD Billion
| 2025 –2032 | |
|
|
USD 781.19 Million |
| USD 1,145.40 Million | |
| % | |
Global Acquired (Autoimmune) Hemolytic Anemia Market Segmentation, Types (Warm Autoimmune Induced Hemolytic Anemia, Cold Agglutinin Disease (CAD) and Others), Treatment (Medication, Blood Transfusion, Surgery, Splenectomy, Others), Diagnosis (Blood Tests, Coombs Test, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2032
Hemolytic anemia is a type of anemia that occurs when your red blood cells break down or die quicker than your body can replace them with new ones. Hemolytic anemia can be caused by inheriting anemia-causing genetic disorders, infections, or specific drugs. Hemolytic anemia treatment varies based on the origin of the sickness. Blood transfusions, corticosteroid medications, and Rituximab are all possible treatments. Surgery to remove the spleen is recommended in more severe cases. Warm antibody hemolytic anemia and cold antibody hemolytic anemia are two types of acquired (autoimmune) hemolytic anemia. Autoantibodies attach to red blood cells in warm antibody hemolytic anemia and destroy them at a temperature higher than body temperature; in cold antibody hemolytic anemia, self-generated antibodies kill red blood cells at a temperature lower than body temperature.
Global acquired (autoimmune) hemolytic anemia market size was valued at USD 781.19 million in 2024 and is projected to reach USD 1145.40 million by 2032, with a CAGR of 4.90% during the forecast period of 2025 to 2032.
Report Scope and Market Segmentation
|
Attributes
|
Acquired (Autoimmune) Hemolytic Anemia Key Market Insights
|
|
Segmentation
|
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Key Market Players
|
Fresenius SE & Co. KGaA (Germany), Sanofi (France), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), AbbVie Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd.(Ireland), Lupin (India), ViforPharma Ltd. (Switzerland), AMAG Pharmaceuticals (U.S.), Akebia Therapeutics, INC. (U.S.), CHO-A Pharmaceutical CO., LTD. (South Korea), Orion Corporation (Finland), Pharmacosmos A/S (Denmark), Shield Therapeutics (U.K.), Advanz Pharmaceutical (U.K.), Alkem Labs (India), Zydus Cadila (India), and Hikma Pharmaceuticals PLC (U.K.)
|
|
Market Opportunities
|
|
Acquired (Autoimmune) Hemolytic Anemia Market Definition
Non-genetic acquired (autoimmune) hemolytic anemia arises when the body's own immune system eliminates healthy tissues in response to invading organisms such as lymphocytes and antibodies. The treatment focuses on three main goals: preventing RBC destruction, raising RBC count, and treating the underlying ailment. Major treatment options include blood transfusions, medicines, plasmapheresis, and procedures. To treat acquired (autoimmune) hemolytic anemia, medicines such as prednisone, rituximab, hydroxyurea, and cyclosporine are commonly used.
Acquired (Autoimmune) Hemolytic Anemia Market Dynamics
Drivers
The rising prevalence of iron-deficiency anemia is estimated to influence the market's growth rate. Along with this, the growing incidences of autoimmune diseases such as lupus, rheumatoid arthritis, Sjogren's syndrome, thyroid disease, Hashimoto's disease and ulcerative colitis will influence the market dynamics during the forecast period.
Another significant factor influencing the growth rate of acquired (autoimmune) hemolytic anemia market is the rising healthcare expenditure, which helps improve its infrastructure. Also, various government organizations aim to improve the healthcare infrastructure by increasing funding, which will further influence the market dynamics.
The increasing number of geriatric population is estimated to enhance the market's growth rate. According to the World Ageing 2020 estimate, there will be 727 million people aged 65 and up in the year 2020. In 2050, this population is expected to increase to 1.5 billion. The proportion of the geriatric population is estimated to rise. The elderly population is more prone to acquired (autoimmune) hemolytic anemia, further enhancing the market's growth rate. Acquired (autoimmune) hemolytic anemia can affect people of all ages and genders, though it most commonly occurs in females over the age of 40.
Furthermore, a surging number of government initiatives to spread awareness and sedentary lifestyle will result in the expansion of acquired (autoimmune) hemolytic anemia market. Along with this, rising level of disposable income and increase in the risk of haemodilution will enhance the market's growth rate.
Opportunities
The market's growth is fueled by growing number of research and development activities. This will provide beneficial opportunities for the acquired (autoimmune) hemolytic anemia market growth.
Moreover, the market's growth is fueled by investment to develop advanced technologies and increase the number of emerging markets. These factors will provide beneficial opportunities for the acquired (autoimmune) hemolytic anemia market growth.
Restraints/Challenges
On the other hand, the high cost associated with the treatment will obstruct the growth rate of the acquired (autoimmune) hemolytic anemia market during 2025-2032. The lack of healthcare infrastructure in developing economies and the dearth of skilled professionals will challenge the acquired (autoimmune) hemolytic anemia market. Additionally, lack of awareness among people and poor reimbursement policies will restrain and further impede the market's growth rate during the forecast period of 2025-2032.
This acquired (autoimmune) hemolytic anemia market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the acquired (autoimmune) hemolytic anemia market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
Autoimmune hemolytic anemia is rare, affecting approximately 1 to 2 of every 100,000 people yearly.
The acquired (autoimmune) hemolytic anemia market also provides detailed market analysis for patient analysis, prognosis, and cures. Prevalence, incidence, mortality, and adherence rates are some data variables available in the report. Direct or indirect impact analyses of epidemiology to market growth are analyzed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
The acquired (autoimmune) hemolytic anemia market is segmented on the basis of types, treatment, diagnosis, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Types
Treatment
Diagnosis
Route of Administration
End-Users
Distribution Channel
The acquired (autoimmune) hemolytic anemia market is analyzed and market size insights and trends are provided by country, types, treatment, diagnosis, route of administration, end-users and distribution channel as referenced above.
The countries covered in the acquired (autoimmune) hemolytic anemia market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America and Europe dominate the acquired (autoimmune) hemolytic anemia market because of the well-established healthcare infrastructure in this region. Additionally, the growing focus of major key players on novel technology will further propel the market's growth rate in this region.
Asia-Pacific is expected to be the fastest-growing region during the forecast period of 2025-2032 due to the growing number of patient populations and the large number of generic manufacturers in this region. Also, development of healthcare infrastructure and rising government initiatives will further propel the market's growth rate in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
The acquired (autoimmune) hemolytic anemia market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to acquired (autoimmune) hemolytic anemia market.
Acquired (Autoimmune) Hemolytic Anemia Market Leaders Operating in the Market Are:
SKU-
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.